PATENT CLAIM ANALYSIS

Application Number: 16181747
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "235500"]

Abstract:
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.

Claim (Index 1):
A method for treating non-Hodgkin's lymphoma (NHL) comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the NHL is selected from diffuse large B-cell lymphoma (DLBCL), a germinal center-derived lymphoma, a non-germinal center-derived lymphoma, follicular lymphoma (FL), primary mediastinal large B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), Burkitt's lymphoma and other non-Hodgkin's lymphoma subtype.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 98.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15319535', '15809445', '15567838', '13949026', '14540977']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7441005720387237
- 35 USC 102 Novelty (BERT): 0.5421298169128593
- Combined Prediction Score: 0.7239034965261373
- Mean Citation Score: 269.48406600000004
- Max Citation Score: 384.1392
- Similarity Product: 300.98229652633665

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test